Innovus (INNV): Twenty-Eight Drugs in Five Years. (San Diego Reader)
(Originally published 4/25/2018)
“I am very steady. I like to work slowly, but surely, to get to my goal.”...
Adding Innovus Pharma (INNV) $2.50 to Watch List.
Fast Growing eCommerce and Direct to Consumer Pharma Company Announces 1st Foray into CBD and 2nd Major Off-Patent Blockbuster Drug to its...
Innovus Pharma (INNV) Partners With Lavasta’s 150 Member Sales Force for Female Sexual Arousal!
Dubai based Lavasta is a pharmaceutical marketing company that offers niched unique medications based on the latest scientific innovations that defy current...
Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.
CRANFORD, N.J., May 13, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug...
Rogaine® Competitor Regoxidine™ Expected to Launch Second Half, 2019.
Innovus Pharma (INNV) Announces a Second Partnered United States OTC ANDA for Minoxidil 5% Foam for Men and Women.
3M to Acquire Wound Care Technology Co., Acelity for $6.7 Billion.
Chronic wounds represent a large and growing threat to public health. In the US alone, they affect over 6.5 million people. As...
Lift Off! Mustang Bio (MBIO) $9.31 Jumps 4-Fold.
‘Bubble Boy’ Biotech Soars 250 Percent After Cure Announcement (Bloomberg).
(Bloomberg) -- Shares of the tiny biotechnology company...
Adding Vaccinex (VCNX) $5.50, to Watch List After Investor Presentation.
IPO Tumbles in Aftermarket, from $12 underwritten by Oppenheimer, BTIG and Ladenburg Thalmann, to a low of $3 in six months.
Latest article
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we...
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
